Regorafenib in gastrointestinal stromal tumors: Clinical evidence and place in therapy

Therapeutic Advances in Medical Oncology

Volumn 6, Issue 5, 2014, Pages 222-228

  Ferraro, Danielle ^a   Zalcberg, John ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

gastrointestinal stromal tumors; regorafenib; targeted therapies

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IMATINIB; IRINOTECAN; REGORAFENIB; SUNITINIB;

ADVERSE OUTCOME; CANCER CHEMOTHERAPY; DRUG APPROVAL; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LICENSING; MULTICENTER STUDY (TOPIC); NONHUMAN; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STANDARD;

EID: 84908160251     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834014544892     Document Type: Review

References (29)

1. Agaimy A. Wunsch P. Hofstaedter F. Blaszyk H. Rümmele P. Gaumann A. et al. (2007) Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 31: 113–120.
2. Corless C. Schroeder A. Griffith D. Town A. McGreevey L. Harrell P. et al. (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23: 5357-5364.
3. Debiec-Rychter M. Cools J. Dumez H. Sciot R. Stul M. Mentens H. et al. (2005) Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC 412 inhibitor against imatinib-resistant mutants. Gastroenterology 128: 270–279.
4. Debiec-Rychter M. Dumez H. Judson I. Wasag B. Verweij J. Brown M. et al. (2004) PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40: 689–695.
5. deGramont A. van Cutsem E. Schmoll H. Tabernero J. Clarke S. Moore M. et al. (2012) Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 13: 1225-1233.
6. de Matteo R. Ballman K. Antonescu C. Maki R. Pisters P. Demetri G. et al. (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373: 1097-1104.
7. Demetri G. Reichardt P. Kang Y. Blay J. Rutkowski P. Gelderblom H. et al. (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381: 295-302.
8. Demetri G. van Oosterom A. Garrett C. Blackstein M. Shah M. Verweij J. et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet 368: 1329–1338.
9. Edmonson J. Marks R. Buckner J. Mahoney M. (2002) Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 20: 605-612.
10. Gastrointestinal Stromal Tumor Meta-Analysis Group (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 28: 1247-1253.
11. George S. Wang Q. Heinrich M. Corless C. Zhu M. Butrynski J. et al. (2012) Efficacy and safety of regorafenib in patients with metastatic and / or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicentre phase II trial. J Clin Oncol 30: 2401-2407.
12. Grothey A. George S. van Cutsem E. Blay J-Y. Sobrero A. Demetri G. (2014) Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. The Oncologist 19: 669-680.
13. Grothey A. van Cutsem E. Sobrero A. Siena S. Falcone A. Ychou M. et al. (2013). Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381: 303-312.
14. Hantschel O. Rix U. Superti-Furga G. (2008) Target spectrum of BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 49: 615-619.
15. Heinrich M. Corless C. Blanke C. Demetri G. Joensuu H. Roberts P. et al. (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24: 4764–4774.
16. Heinrich M. Corless C. Demetri G. Blanke C. von Mehren M. Joensuu H. et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349.
17. Heinrich M. Owzar K. Corless C. Hollis D. Borden E. Fletcher C. et al. (2008) Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26: 5360-5367.
18. Hirota S. Isozaki K. Moriyama Y. Hashimoto K. Nishida T. Ishiguro S. et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577–580.
19. Joensuu H. Eriksson M. Sundby Hall K. Hartmann J. Pink D. Schütte J. et al. (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307: 1265-1272.
20. Kawanowa K. Sakuma Y. Sakurai S. Hishima T. Iwasaki Y. Saito K. et al. (2006) High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 37:1527-1535.
21. Kindblom L. Remotti H. Aldenborg F. Meis-Kindblom J. (1998) Gastrointestinal pacemaker cell tumor (GIPACT) – gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152: 1259–1269.
22. Kinoshita K. Isozaki K. Hirota S. Nishida T. Chen H. Nakahara M. et al. (2003) c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors. J Gastroenterol Hepatol 18: 147-151.
23. Miettinen M. Lasota J. (2006) Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130: 1466-1478.
24. Mross K. Frost A. Steinbild S. Hedbom S. Buchert M. Fasol U. et al. (2012) A phase I dose escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18: 2658-2667.
25. Muenst S. Thies S. Went P. Tornillo L. Bihl M. Dirnhofer S. (2011) Frequency, phenotype, and genotype of minute gastrointestinal stromal tumors in the stomach: an autopsy study. Hum Pathol 42: 1849-1854.
26. Park S. Davis M. Doroshow J. Kummar S. (2013) Safety and feasibility of targeted agent combinations in solid tumours. Nat Rev Clin Oncol 10: 154-168.
27. Sajithlal G. Hamed H. Cruickshanks N. Booth L. Tavallai S. Syed J. et al. (2013) Sorafenib / regorafenib and phosphatidyl inositol 3 kinase / thymoma viral proto-oncogene inhibition interact to kill tumor cells. Mol Pharmacol 84: 562-571.
28. Screening for mutations in circulating DNA (2013) Cancer Discovery 3: 476.
29. Wilhelm S. Dumas J. Adnane L. Lynch M. Carter C. Schutz G. et al. (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129: 245–255.